Ratings MediPharm Labs Corp.

Equities

LABS

CA58504D1006

Delayed Toronto S.E. Other stock markets 03:12:14 2024-05-15 pm EDT			5-day change	1st Jan Change
0.08 ^CAD	-5.88%		0.00%	+30.77%

01:50pm	MediPharm Labs Q1 Gross Profit, Rise	MT
12:36pm	MediPharm Labs Corp. Brief: Anticipates further improvement on profitability in 2024 with plans being implemented to improve Adjusted EBITDA by a further $1-$2 Million	MT

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
MEDIPHARM LABS CORP.	+38.46%	25.17M		D
DONG-E-E-JIAO CO.,LTD.	+44.36%	6.34B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-13.52%	4.61B		C+
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+9.54%	3.39B		C
TASLY PHARMACEUTICAL GROUP CO., LTD	-8.99%	3.29B		B-
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+50.03%	2.02B		-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-6.97%	1.73B	-	-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+1.29%	1.67B	-	-
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+57.69%	1.63B		-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-9.67%	1.59B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes